Trivedon MR (Trimetazidine Dihydrochloride Extended Release Tablets 35mg)

Country: Malaysia

Language: English

Source: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Active ingredient:

TRIMETAZIDINE DIHYDROCHLORIDE

Available from:

CIPLA MALAYSIA SDN BHD

INN (International Name):

TRIMETAZIDINE DIHYDROCHLORIDE

Units in package:

100Tablet Tablets

Manufactured by:

CIPLA LTD

Patient Information leaflet

NOT FOUND
The requested URL /front-end/attachment/39070/pharma/228571/Trivedon
MR ENG & BM RIMUP.pdf was not found on this server.

Summary of Product characteristics

_For the use of a Registered Medical Practitioner or a Hospital or a
Laboratory only _
GENERIC NAME
TRIMETAZIDINE DIHYDROCHLORIDE EXTENDED RELEASE TABLETS 35 MG
BRAND NAME
TRIVEDON MR
COMPOSITION
Trivedon MR
Each film coated extended release tablet contains:
Trimetazidine Dihydrochloride Ph.Eur ………… 35 mg
DOSAGE FORM
Tablets
PRODUCT DESCRIPTION
White to off-white circular biconvex, film coated tablets plain on
both sides with aperture on
one face.
PHARMACOLOGY
_PHARMACODYNAMICS_
Trimetazidine is a unique anti-ischaemic drug, which protects the
myocardial cell from the harmful
effects of ischaemia.
The mode of action is trimetazidine is different from beta-blockers,
calcium channel blockers
and
nitrates.
Unlike
these
antianginal
agents,
which
affect
haemodynamic
determinants
of
myocardial oxygen supply-demand balance, trimetazidine prevents the
damage to the myocardial
cell during an ischaemic episode. Trimetazidine inhibits fatty
acid
oxidation
secondary
to
an
inhibition
of
long-chain
3-ketoacyl
CoA
thiolase (KAT), resulting in an increase in glucose
oxidation. This results in switching energy substrate preference from
fatty acid oxidation to the
more efficient glucose oxidation which explains the antianginal
properties. Trimetazidine
prevents intracellular metabolic changes such as depletion of
adenosine triphosphate
(ATP)
and
phosphocreatinine, accumulation of protons, and toxic free radical
generation which result from
ischaemia and reperfusion in the myocardium.
Trimetazidine exerts protective effects against ionic disturbance due
to ischemia- reperfusion in
fatty acid-perfused hearts, but depending on the degree of severity.
Trimetazidine has also been
proven to provide membrane protection through a large increase in
phospholipids turnover. This
effect contributes to a reorganization of fatty acid utilization
balance, resulting in their decreased
availability for energy production. As
such,
trimetazidine
raises
cell
tolerance
to
ischaemia-reperfusion injury. Trimetazidine enhances the metabolic
statu